Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

865 results

• Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03705793).Phase 4Results postedn = 53NCT03705793
• Effectiveness of Pulmozyme in Infants With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Effectiveness of Pulmozyme in Infants With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00179998).Phase 2Results postedn = 24NCT00179998
• Effectiveness of the Aeroneb in Acute Severe Asthma: Complete Statistical AnalysisIndependent statistical analysis of Effectiveness of the Aeroneb in Acute Severe Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03029156).Phase NAResults postedn = 31NCT03029156
• Effects of a Common Cold Treatment on Cognitive Function: Complete Statistical AnalysisIndependent statistical analysis of Effects of a Common Cold Treatment on Cognitive Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01466348).Phase 4Results postedn = 72NCT01466348
• Effects of Broccoli Sprout Extract on Allergy Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of Effects of Broccoli Sprout Extract on Allergy Rhinitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02885025).Phase 2Results postedn = 47NCT02885025
• Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction: Complete Statistical AnalysisIndependent statistical analysis of Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 13NCT02579772
• Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.: Complete Statistical AnalysisIndependent statistical analysis of Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04871815).Phase 2/3Results postedn = 22NCT04871815
• Effects of Whole Sprouts on Airway Allergic Inflammation: Complete Statistical AnalysisIndependent statistical analysis of Effects of Whole Sprouts on Airway Allergic Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01522703).Phase NAResults postedn = 51NCT01522703
• Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 355NCT01527188
• Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 403NCT01634139
• Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 465NCT01316380
• Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 105NCT01122680
• Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 944NCT04123405
• Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD): primary endpoint…Phase 3Results postedn = 112NCT01471171
• Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium: primary endpoint…Phase 2Results postedn = 83NCT00501852
• Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 342NCT03551210
• Efficacy and Safety of Omalizumab in Children (6 – < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 628NCT00079937
• Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 172NCT03840135
• Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults: primary endpoint results,…Phase 3Results postedn = 224NCT01667731
• Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 168NCT02556801
• Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 388NCT00350207
• Efficacy and Safety Study in Subjects With Asthma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study in Subjects With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00980200).Phase 2Results postedn = 75NCT00980200
• Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 87NCT01746095
• Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor): Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 21NCT00396006
• Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 3NCT01388920
• Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 12,794NCT03739112
• Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 30NCT00868231
• Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 569NCT02072174
• Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 178NCT00847808
• Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01391559).Phase NAResults postedn = 20NCT01391559
• Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05144828).Phase 4Results postedn = 33NCT05144828
• Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 30NCT00927901
• Efficiency of the King Vision Video Laryngoscope: Complete Statistical AnalysisIndependent statistical analysis of Efficiency of the King Vision Video Laryngoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02482870).Phase NAResults postedn = 388NCT02482870
• EinsteinChoiceComplete statistical analysis of the EinsteinChoice phase 3 trial of reduced-dose rivaroxaban for long-term prevention of recurrent symptomatic venous thromboembolism, including trial design, endpoints, hazard ratios, confidence intervals, safety, and statistical interpretation.Phase 3Results postedn = 3,365NCT02064439
• Electric Muscle Stimulation for Patients With Chronic Respiratory Failure: Complete Statistical AnalysisIndependent statistical analysis of Electric Muscle Stimulation for Patients With Chronic Respiratory Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01930643).Phase NAResults postedn = 13NCT01930643
• Elucidation of Acid-Induced Pulmonary Inflammation: Complete Statistical AnalysisIndependent statistical analysis of Elucidation of Acid-Induced Pulmonary Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361972).Phase 2/3Results postedn = 17NCT00361972
• EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients: Complete Statistical AnalysisIndependent statistical analysis of EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 200NCT02443688
• EMPROVEIndependent statistical analysis of the EMPROVE randomized trial evaluating the Spiration Valve System for emphysema, including trial design, the primary FEV1 endpoint, planned statistical methodology, and interpretation.Phase NAn = 172NCT01812447
• EMTIndependent statistical analysis of Enhanced Community-Based Asthma Monitoring Through Novel Technology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05824936).Phase NAResults postedn = 15NCT05824936
• ENB-GS-TBLB for the Diagnosis of PPLs: Complete Statistical AnalysisIndependent statistical analysis of ENB-GS-TBLB for the Diagnosis of PPLs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02207478).Phase NAResults postedn = 80NCT02207478
• Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00778648).Phase NAResults postedn = 543NCT00778648
• Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle: Complete Statistical AnalysisIndependent statistical analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 61NCT03004586
• endTBIndependent statistical analysis of the phase 3 endTB trial (NCT02754765), evaluating newly approved drugs for multidrug-resistant tuberculosis, including trial design, the week 73 efficacy endpoint, planned statistical analysis, and interpretation.Phase 3n = 754NCT02754765
• endTB-QIndependent statistical analysis of the phase 3 endTB-Q trial evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance.Phase 3n = 323NCT03896685
• ENDUREIndependent statistical analysis of A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis…Phase 2Results postedn = 251NCT05375760
• Enhancing Plasticity in Stroke Patients With Severe Motor Deficit: Complete Statistical AnalysisIndependent statistical analysis of Enhancing Plasticity in Stroke Patients With Severe Motor Deficit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02633215).Phase NAResults postedn = 36NCT02633215
• EOLIAAn independent statistical analysis of the EOLIA randomized trial of extracorporeal membrane oxygenation versus conventional care for severe acute respiratory distress syndrome, including trial design, the day-60 mortality endpoint, planned time-to-event analysis,…Phase NAn = 249NCT01470703
• EPIC-PEDSA detailed statistical analysis of EPIC-PEDS, a phase 3 single-group study of nirmatrelvir/ritonavir in patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe…Phase 3n = 160NCT05261139
• EPIC-SRIndependent statistical analysis of EPIC-SR (NCT05011513), the randomized, placebo-controlled phase 2/3 trial of nirmatrelvir plus ritonavir in standard-risk COVID-19, covering the log-rank primary analysis, logistic-regression odds ratios, negative binomial modelling and serious…Phase 2/3Results postedn = 1,440NCT05011513
• ERA-PAHIndependent statistical analysis of Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02911844).Phase 2Results postedn = 5NCT02911844

← All therapeutic areas